pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer
AstraZeneca
AstraZeneca AB
AstraZeneca clinical programs — 120 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 249
- Drugs
- 238
- Patents
- 2
AstraZeneca projects
120 ClinicalTrials.gov programs sponsored by AstraZeneca.
AstraZeneca has 120 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
D967RC00001
AstraZeneca AB
Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory)
1 trial -
D967SC00001
AstraZeneca AB
Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations
1 trial -
D967UC00001
AstraZeneca AB
HER2-positive metastatic breast cancer
1 trial -
D9722C00001
AstraZeneca AB
Advanced Breast Cancer
1 trial -
D9723C00001
AstraZeneca AB
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
1 trial -
D9727C00001
AstraZeneca AB
Prostate Cancer
1 trial -
D9802C00001
AstraZeneca AB
Gastric cancer, Advanced/Metastatic Gastric cancer, Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
1 trial -
DANUBE/D419BC00001
AstraZeneca AB
Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naïve.
1 trial -
DESTINYEndometrial01
AstraZeneca AB
HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer
1 trial -
DUO-O/D081RC00001
AstraZeneca AB
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer
1 trial -
Datopotamab deruxtecan for Stage I-III Triple-negative Bre…
AstraZeneca AB
Stage I-III Triple-negative Breast Cancer with residual invasive disease after neoadjuvant systemic therapy.
1 trial -
Datopotamab deruxtecan, DOCETAXEL
AstraZeneca AB
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.
1 trial -
EMERALD-1
AstraZeneca AB
Locoregional Hepatocellular Carcinoma (HCC)
1 trial -
GEMCITABINE for Patients with histologically or…
AstraZeneca AB
Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder
1 trial -
IRIS, D3466C00001
AstraZeneca AB
Active Proliferative Lupus Nephritis
1 trial -
JOURNEY
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
KOMET D134BC00001
AstraZeneca AB
Neurofibromatosis Type 1 (NF1) with Symptomatic, Inoperable Plexiform Neurofibromas (PN).
1 trial -
PACIFIC2/D933KC00001
AstraZeneca AB
Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)
1 trial -
PROpel D081SC00001
AstraZeneca AB
Metastatic castration-resistant prostate cancer
1 trial -
SOLO 1-D0818C00001
AstraZeneca AB
BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer
1 trial -
Tezspire 210 mg solution for injection in pre-filled syringe
AstraZeneca AB
Chronic Rhinosinusitis with Nasal Polyposis
1 trial -
Tezspire 210 mg solution for injection in pre-filled syringe
AstraZeneca AB
Severe Asthma
1 trial -
Tozorakimab, Tozorakimab-placebo
AstraZeneca AB
Severe viral lung infections
1 trial -
Tropion-Breast05
AstraZeneca AB
Triple-negative Breast Cancer
1 trial
Frequently asked questions
How many clinical projects does AstraZeneca have?
120 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.